/ 2 items

#XENE↓

XENE/ 03/09/2026 · 7:41 AM

Xenon’s Azetukalner Shows Record Efficacy in Phase 3 Epilepsy Trial

Xenon Pharmaceuticals reported strong Phase 3 results for azetukalner in focal onset seizures. The drug reduced monthly seizures by 53.2% vs 10.4% on placebo. NDA filing planned for Q3 2026.

Featured/ BHVN/ 12/26/2025 · 6:00 AM

Biohaven's Depression Drug BHV-7000 Falls Short in Clinical Trial

Biohaven's (BHVN) experimental depression treatment BHV-7000 didn't meet its primary goal in Phase 2 testing, though some patient subgroups showed promising trends.